SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                (Date of earliest event reported): August 1, 2003

                           ARIAD PHARMACEUTICALS, INC.
              ----------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)


                Delaware                     0-21696               22-3106987
                --------                     -------               ----------
     (State or Other Jurisdiction   (Commission File Number)  (I.R.S. Employer
         of Incorporation)                                   Identification No.)


                              26 LANDSDOWNE STREET
                         CAMBRIDGE, MASSACHUSETTS 02139
              (Address of principal executive offices and zip code)


               Registrant's telephone number, including area code:
                                 (617) 494-0400























ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.


           (c) Exhibits.

              99.1 The Registrant's Press Release dated August 1, 2003.

              This Press Release is being furnished pursuant to Item 12 of this
              Current Report on Form 8-K and shall not be deemed "filed" for
              purposes of Section 18 of the Securities Exchange Act of 1934 (the
              "Exchange Act") or otherwise subject to the liabilities of that
              Section, nor shall it be deemed incorporated by reference in any
              filing under the Securities Act of 1933 or the Exchange Act.

ITEM 12.      RESULTS OF OPERATIONS AND FINANCIAL CONDITION

              On August 1, 2003, ARIAD Pharmaceuticals, Inc. announced its
              financial results for the three months ended June 30, 2003. A copy
              of the Press Release is furnished pursuant to this Item 12 as
              Exhibit 99.1 to this Current Report on Form 8-K.


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                   ARIAD PHARMACEUTICALS, INC.



                                   By:    /s/ Edward M. Fitzgerald
                                          ------------------------
                                          Edward M. Fitzgerald
                                          Senior Vice President and
                                          Chief Financial Officer


Date:    August 1, 2003


                                       2





                                  EXHIBIT INDEX

Exhibit
Number   Description                                      Sequential Page Number
-------  -----------                                      ----------------------

99.1     The Registrant's Press Release dated August 1, 2003.         4


                                       3